Literature DB >> 11986956

Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR.

V H J van der Velden1, M J Willemse, C E van der Schoot, K Hählen, E R van Wering, J J M van Dongen.   

Abstract

Immunoglobulin gene rearrangements are used as PCR targets for detection of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL). We investigated the occurrence of monoclonal immunoglobulin kappa-deleting element (IGK-Kde) rearrangements by Southern blotting and PCR/heteroduplex analysis at diagnosis, their stability at relapse, and their applicability in real-time quantitative PCR (RQ-PCR) analysis. In 77 selected children with precursor-B-ALL, Southern blotting detected 122 IGK-Kde rearrangements, 12 of which were derived from subclones in six patients (8%). PCR/heteroduplex analysis with BIOMED-1 Concerted Action primers identified 100 of the 110 major IGK-Kde rearrangements (91%). Comparison between diagnosis and relapse samples from 21 patients with PCR-detectable IGK-Kde rearrangements (using Southern blotting, PCR/heteroduplex analysis, and sequencing) demonstrated that 27 of the 32 rearrangements remained stable at relapse. When patients with oligoclonal IGK-Kde rearrangements were excluded, 25 of the 27 rearrangements remained stable at relapse and at least one stable rearrangement was present in 17 of the 18 patients. Subsequently, RQ-PCR analysis with allele-specific forward primers, a germline Kde TaqMan-probe, and a germline Kde reverse primer was evaluated for 18 IGK-Kde rearrangements. In 16 of the 18 targets (89%) a sensitivity of < or =10(-4) was reached. Analysis of MRD during follow-up of eight patients with IGK-Kde rearrangements showed comparable results between RQ-PCR data and classical dot-blot data. We conclude that the frequently occurring IGK-Kde rearrangements are generally detectable by PCR (90%) and are highly stable MRD-PCR targets, particularly where monoclonal rearrangements at diagnosis (95%) are concerned. Furthermore, most IGK-Kde rearrangements (90%) can be used for sensitive detection of MRD (< or =10(-4)) by RQ-PCR analysis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11986956     DOI: 10.1038/sj.leu.2402475

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  18 in total

1.  Consensus JH gene probes with conjugated 3'-minor groove binder for monitoring minimal residual disease in acute lymphoblastic leukemia.

Authors:  Michihiro Uchiyama; Chihaya Maesawa; Akiko Yashima-Abo; Mitsu Tarusawa; Mikiya Endo; Waka Sugawara; Shoichi Chida; Shima Onodera; Yasuhiko Tsukushi; Yoji Ishida; Shigeru Tsuchiya; Tomoyuki Masuda
Journal:  J Mol Diagn       Date:  2005-02       Impact factor: 5.568

2.  Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis.

Authors:  Jana Volejnikova; Ester Mejstrikova; Tatana Valova; Leona Reznickova; Ladislava Hodonska; Vladimir Mihal; Jaroslav Sterba; Yahia Jabali; Daniela Prochazkova; Bohumir Blazek; Jiri Hak; Zdenka Cerna; Ondrej Hrusak; Jan Stary; Jan Trka; Eva Fronkova
Journal:  Haematologica       Date:  2011-08-31       Impact factor: 9.941

Review 3.  Microarrays, antiobesity and the liver.

Authors:  Fernando Castro-Chávez
Journal:  Ann Hepatol       Date:  2004 Oct-Dec       Impact factor: 2.400

4.  Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL.

Authors:  M Kotrova; V H J van der Velden; J J M van Dongen; R Formankova; P Sedlacek; M Brüggemann; J Zuna; J Stary; J Trka; E Fronkova
Journal:  Bone Marrow Transplant       Date:  2017-02-27       Impact factor: 5.483

5.  Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.

Authors:  Prisca Theunissen; Ester Mejstrikova; Lukasz Sedek; Alita J van der Sluijs-Gelling; Giuseppe Gaipa; Marius Bartels; Elaine Sobral da Costa; Michaela Kotrová; Michaela Novakova; Edwin Sonneveld; Chiara Buracchi; Paola Bonaccorso; Elen Oliveira; Jeroen G Te Marvelde; Tomasz Szczepanski; Ludovic Lhermitte; Ondrej Hrusak; Quentin Lecrevisse; Georgiana Emilia Grigore; Eva Froňková; Jan Trka; Monika Brüggemann; Alberto Orfao; Jacques J M van Dongen; Vincent H J van der Velden
Journal:  Blood       Date:  2016-11-30       Impact factor: 22.113

6.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Authors:  Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta
Journal:  Blood       Date:  2008-04-03       Impact factor: 22.113

7.  Flow cytometry and polymerase chain reaction-based analyses of minimal residual disease in chronic lymphocytic leukemia.

Authors:  Sabrina Uhrmacher; Felix Erdfelder; Karl-Anton Kreuzer
Journal:  Adv Hematol       Date:  2010-09-20

8.  Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: a report from the AIEOP registry.

Authors:  Franca Fagioli; Paola Quarello; Marco Zecca; Edoardo Lanino; Carla Rognoni; Adriana Balduzzi; Chiara Messina; Claudio Favre; Roberto Foà; Mimmo Ripaldi; Sergio Rutella; Giuseppe Basso; Arcangelo Prete; Franco Locatelli
Journal:  Haematologica       Date:  2013-02-26       Impact factor: 9.941

9.  Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.

Authors:  N Puig; M E Sarasquete; A Balanzategui; J Martínez; B Paiva; H García; S Fumero; C Jiménez; M Alcoceba; M C Chillón; E Sebastián; L Marín; M A Montalbán; M V Mateos; A Oriol; L Palomera; J de la Rubia; M B Vidriales; J Bladé; J J Lahuerta; M González; J F S Miguel; R García-Sanz
Journal:  Leukemia       Date:  2013-07-17       Impact factor: 11.528

10.  Implementation of the standard strategy for identification of Ig/TCR targets for minimal residual disease diagnostics in B-cell precursor ALL pediatric patients: Polish experience.

Authors:  Małgorzata Dawidowska; Justyna Jółkowska; Tomasz Szczepański; Katarzyna Derwich; Jacek Wachowiak; Michał Witt
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-12-01       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.